Craig Morgan, Head of Marketing, goBalto11.07.17
In human clinical trials, especially Phase III, represent by far the largest part of the substantial cost1 of bringing new drugs to market. Over the last several decades as the size, complexity, length, cost and globalization of clinical trials has continued to grow, the importance of contract research organizations (CROs) to the pharmaceutical and biotech industries has increased significantly. Outsourcing has become a popular way for pharmaceutical companies to utilize on-demand services to improve operational efficiency and therapeutic expertise, cut costs, and add more extensive geographic capabilities.
As demand for their services has intensified, the CRO industry has responded with a growing movement towards consolidation in order to expand capabilities and reach to service large global studies. Recently, there have been a number of noteworthy mergers and acquisitions (M&As):
One of the more interesting features of this consolidation trend is private equity (PE) companies purchasing CROs.12 The proliferation of CRO purchases by PE firms in recent years is an indication that wall street understands that significant profit can be made when real improvements are made in CROs after M&As—the CRO market has in fact been one of the best performing sectors in recent years in financial circles.
But just because CRO M&As are good for wall street, does not necessarily mean they are good for the pharmaceutical industry as a whole.
Benefits of CRO consolidation
Sponsors of large, global Phase III clinical trials want a competitive CRO market with plenty of quality CROs with global reach to choose from. These sponsors are also looking to form strategic partnerships and preferred provider arrangements with just a few large CROs, as this is far easier to manage.13
From a CRO perspective, winning one large $200-300 million Phase III study can be a huge benefit for the bottom line. As a result, there is pressure within the CRO industry for mergers as a way to quickly expand reach into places like the Middle East, North Africa and parts of Asia other than China and India, in order to be attractive to large sponsors. Additionally, mergers can provide a quick way for CROs to expand their offerings beyond clinical services in order to attract business from all aspects of the drug development lifecycle.
This M&A trend in the CRO industry provides a number of benefits for sponsors:
While the CRO consolidation phenomenon is overall a positive trend for the pharmaceutical industry, there are some drawbacks to consider:
How do CROs compare to sponsors?
Is this outsourcing trend justified by gains in study conduct efficiencies? The study startup phase of a trial has been receiving renewed focus from pharmaceutical companies under intense pressure to reduce timelines and abate the rising costs of drug development, as it is notoriously inefficient yet has the biggest impact on overall study timelines, budget, and operational outcomes. In an effort to gather robust, quantitative insights into the factors that drive an effective and efficient site identification, selection, feasibility assessment, and activation process, Tufts Center for the Study of Drug Development (CSDD) conducted an in-depth survey of biopharmaceutical and CRO organizations.14 The START (Start-up Time And Readiness Tracking) II Study, conducted in early 2017 consisted of 591 individual respondents (313 from sponsors, 139 from CROs) from 403 unique organizations represented.
The study yielded some very interesting insights regarding the current state of the industry:
Conclusion
The CRO consolidation phenomenon will likely continue into the foreseeable future with large CROs acquiring smaller, boutique CROs known for their regulatory and therapeutic focus. While CRO M&As can contribute in a significant way towards improving clinical trials, mergers in any industry are difficult to undertake, especially in terms of cultural differences, IT and tax considerations involved in consolidating international enterprises.
Research from Tufts CSDD shows technology adoption in the CRO market continues to rise, making these players important innovators in the R&D value chain. That said, CRO mergers are likely to affect the agility and speed of operations and may hamper efforts to bring in new technologies. Nevertheless, when integrated effectively, CRO mergers can add significant value to both the pharmaceutical industry and the patients who depend on the life-saving medicines it produces.
References
Craig Morgan is a technology and life sciences management professional with more than 15 years experience in the application of informatics and bioinformatics to drug discovery. He currently heads up the marketing and brand development functions at goBalto, working with sponsors, CROs and sites to reduce cycle times and improve collaboration and oversight in clinical trials.
As demand for their services has intensified, the CRO industry has responded with a growing movement towards consolidation in order to expand capabilities and reach to service large global studies. Recently, there have been a number of noteworthy mergers and acquisitions (M&As):
- InVentiv Health and INC Research merged to form one of the world’s largest CROs with net revenues estimated at $3.2 billion.2
- Quintiles merged with IMS Health to improve trail execution using patient data, creating a company with market cap of around $18 billion.3
- Qunitiles also recently acquired DrugDev,4 a technology company that has built one of the industry’s largest global investigator networks and data sharing platforms, and Wingspan, an eTMF solutions provider.
- PPD acquired Acurian to gain analytics-driven feasibility capabilities.5
- LabCorp acquired Covance for collective data resources to drive greater R&D productivity6 and recently announced its pending acquisition of the CRO Chiltern.7
- SynteractHCR was acquired by Amulet Capital Partners.8
- Parexel to be acquired by Pamplona Capital.9
- PRA Health Sciences acquired Symphony Health Solutions in order to integrate healthcare analytics with their clinical research services.10
One of the more interesting features of this consolidation trend is private equity (PE) companies purchasing CROs.12 The proliferation of CRO purchases by PE firms in recent years is an indication that wall street understands that significant profit can be made when real improvements are made in CROs after M&As—the CRO market has in fact been one of the best performing sectors in recent years in financial circles.
But just because CRO M&As are good for wall street, does not necessarily mean they are good for the pharmaceutical industry as a whole.
Benefits of CRO consolidation
Sponsors of large, global Phase III clinical trials want a competitive CRO market with plenty of quality CROs with global reach to choose from. These sponsors are also looking to form strategic partnerships and preferred provider arrangements with just a few large CROs, as this is far easier to manage.13
From a CRO perspective, winning one large $200-300 million Phase III study can be a huge benefit for the bottom line. As a result, there is pressure within the CRO industry for mergers as a way to quickly expand reach into places like the Middle East, North Africa and parts of Asia other than China and India, in order to be attractive to large sponsors. Additionally, mergers can provide a quick way for CROs to expand their offerings beyond clinical services in order to attract business from all aspects of the drug development lifecycle.
This M&A trend in the CRO industry provides a number of benefits for sponsors:
- Increased scalability and geographic presence. As CROs expand their global reach through M&As, sponsors gain access to on-demand scalability for their clinical trials.
- Access to additional therapeutic expertise and service capabilities. Many CRO mergers are driven by the desire to add additional therapeutic expertise and service capabilities to their offerings.4 As CROs expand their offerings, sponsors gain the ability to access more services from a single partner.
- Technology improvements. The right technologies, especially for site identification, selection, and startup activities, can make a big impact in shortening clinical timelines and the overall success of a clinical trial. By providing economies of scale, CRO M&As can allow CROs to invest in technologies that significantly improve operational efficiencies and data integrity in clinical trials.
- Cost savings. CRO M&As allow sponsors to have access to “one-stop shopping” with their CRO partners. Sponsors save money through the operational efficiencies that needing fewer partners to run their global trials provides. Additionally, cost savings in the operations of the CRO itself due to economies of scale generated by being a larger enterprise be passed on to sponsors.
While the CRO consolidation phenomenon is overall a positive trend for the pharmaceutical industry, there are some drawbacks to consider:
- Less business for CRO service providers. Those companies that provide services to CROs (e.g., labs, patient recruitment companies, EDC and IRT vendors, etc.) will lose business as their client’s merge.
- Disruptions to clinical trials. There really is never a good time to accomplish a merger. The last thing any sponsor wants to hear is that the CRO that is running their trial was just bought out or is undergoing a merger. Inevitably, in-progress clinical trials will be affected by CROs mergers—labs will likely be shut down in the middle of running the trial, requiring transfer of all data, samples and knowledge to a different site.
- Less CROs for sponsors to choose from. Presently, there are still plenty of CROs for sponsors to consider when looking for a clinical trial partner. However, if this consolidation trend continues, we may eventually reach a tipping point where there are significantly fewer options available.
How do CROs compare to sponsors?
Is this outsourcing trend justified by gains in study conduct efficiencies? The study startup phase of a trial has been receiving renewed focus from pharmaceutical companies under intense pressure to reduce timelines and abate the rising costs of drug development, as it is notoriously inefficient yet has the biggest impact on overall study timelines, budget, and operational outcomes. In an effort to gather robust, quantitative insights into the factors that drive an effective and efficient site identification, selection, feasibility assessment, and activation process, Tufts Center for the Study of Drug Development (CSDD) conducted an in-depth survey of biopharmaceutical and CRO organizations.14 The START (Start-up Time And Readiness Tracking) II Study, conducted in early 2017 consisted of 591 individual respondents (313 from sponsors, 139 from CROs) from 403 unique organizations represented.
The study yielded some very interesting insights regarding the current state of the industry:
- Overall, CROs report completing all site related activities 6-11 weeks faster than sponsors – cycle times working with repeat sites are approximately 6 weeks faster, and approximately 11 weeks faster when working with new sites. Note that research suggests that 30% of sites selected for a typical multi-center study are new;15
- CROs report shorter cycle times across all individual tasks as well (site identification, site selection and overall study startup);
- CROs report making greater investments in technology than do sponsors and report slightly greater levels of satisfaction with their processes than do sponsors; and
- Overall sponsors and CROs have generally consistent views in terms of areas of improvement
Conclusion
The CRO consolidation phenomenon will likely continue into the foreseeable future with large CROs acquiring smaller, boutique CROs known for their regulatory and therapeutic focus. While CRO M&As can contribute in a significant way towards improving clinical trials, mergers in any industry are difficult to undertake, especially in terms of cultural differences, IT and tax considerations involved in consolidating international enterprises.
Research from Tufts CSDD shows technology adoption in the CRO market continues to rise, making these players important innovators in the R&D value chain. That said, CRO mergers are likely to affect the agility and speed of operations and may hamper efforts to bring in new technologies. Nevertheless, when integrated effectively, CRO mergers can add significant value to both the pharmaceutical industry and the patients who depend on the life-saving medicines it produces.
References
- “Cost to Develop and Win Marketing Approval for a New Drug Is $2.6 Billion,” Tufts CSDD Press Release, November 18th, 2014. Available at: http://csdd.tufts.edu/news/complete_story/pr_tufts_csdd_2014_cost_study
- “InVentiv Health, INC Research merger creates top 3 CRO,” BioPharmaDIVE, May 11, 2017. Jacob Bell. Available at: http://www.biopharmadive.com/news/inventiv-health-inc-merger-cro-manufacturing/442550/
- “Quintiles and IMS Health to Combine in ‘Merger of Equals’,” New York Times, May 3, 2016. Chad Bray. Available at: https://www.nytimes.com/2016/05/04/business/dealbook/quintiles-and-ims-health-to-combine-in-merger-of-equals.html
- “On Site: QuintilesIMS to Buy DrugDev,” Journal of Clinical Research Best Practices, Vol. 13, No. 7, July 2017. Available at: http://www.firstclinical.com/journal/2017/1707_OnSite81.pdf
- “PPD Acquires Acurian,” CenterWatch, August 27, 2013. Available at: https://www.centerwatch.com/news-online/2013/08/27/ppd-acquires-acurian/
- “LabCorp Completes Acquisition of Covance,” BusinessWire, February 19th, 2015. Available at: http://www.businesswire.com/news/home/20150219005757/en/LabCorp-Completes-Acquisition-Covance
- “LabCorp just signed a billion-dollar deal for a healthcare company you’ve probably never heard of,” Business Insider, July 31st, 2017. Lydia Ramsey. Available at: http://www.businessinsider.com/labcorp-acquires-chiltern-ma-in-contract-research-organizations-2017-7
- “Amulet Capital Partners, LP Announces Acquisition of SynteractHCR,” Business Wire, May 25, 2016. Available at: http://www.businesswire.com/news/home/20160525006356/en/Amulet-Capital-Partners-LP-Announces-Acquisition-SynteractHCR
- Available at: https://www.parexel.com/company/news-events/press-releases/2017/parexel-international-enters-definitive-agreement-be-acquired-pamplona-capital-management-8810-share-cash
- “PRA Health Sciences to acquire Symphony Health Solutions,” CenterWatch, August 10th, 2017. Available at: https://www.centerwatch.com/news-online/2017/08/10/pra-health-sciences-acquire-symphony-health-solutions/
- Available at: https://www.isrreports.com/reports/2017-edition-of-the-cro-market-size-projections-2016-2021/
- “Private Equity Opportunities in Contract Research Organizations (CROs): Part I,” The Healthcare Investor, August 30th, 2012. Amber Walsh. Available at: http://www.thehealthcareinvestor.com/2012/08/articles/healthcare-services-investing/private-equity-opportunities-in-contract-research-organizations-cros-part-i/
- “Merck Serono and Quintiles Announce Innovative Clinical Development Partnership,” BusinessWire, May 15th, 2013. Available at: http://www.businesswire.com/news/home/20130515005861/en/Merck-Serono-Quintiles-Announce-Innovative-Clinical-Development
- Webinar available at: http://xtalks.com/thankyou-17q057gobalto.ashx
- “Removing the Blinders in Site Selection,” goBalto, August 3rd, 2016. Craig Morgan. Available at: https://www.gobalto.com/hubfs/docs/ArtReprint_11aug_ANP.pdf?t=1504911760804
Craig Morgan is a technology and life sciences management professional with more than 15 years experience in the application of informatics and bioinformatics to drug discovery. He currently heads up the marketing and brand development functions at goBalto, working with sponsors, CROs and sites to reduce cycle times and improve collaboration and oversight in clinical trials.
